Article thumbnail

Gastrointestinal Stromal Tumors: Molecular Mechanisms and Targeted Therapies

By Erinn Downs-Kelly and Brian P. Rubin


Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are diverse not only in their clinical behavior but also in their histologic appearance. GISTs are insensitive to conventional sarcoma chemotherapy and radiation. However GISTs are sensitive to small-molecule tyrosine kinase inhibitors as 85–90% of GISTs have KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations, which drive tumorigenesis. This review will briefly touch on the clinicopathological features of GIST, while the majority of the review will focus on the clinical and treatment ramifications of KIT and PDGFRA mutations found in GIST

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential,”LaboratoryInvestigation,vol.84,no.7,pp.874–883,
  2. (2005). A knock-in mouse model of gastrointestinal stromal tumor harboring Kit
  3. (2004). A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors,”
  4. (2004). A s s o c i a t i o no fp l a t e l e t - d e r i v e dg r o w t hf a c t o rr e c e p t o rα mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors,”
  5. (2006). a u e r ,L .K .Y u ,G .D .D e m e t r i ,a n dJ .A .F l e t c h e r ,“ H e a t shock protein90inhibitioninimatinib-resistantgastrointestinal stromal tumor,”
  6. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation,”
  7. (2009). Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,”
  8. (2003). Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region,”
  9. (2006). Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors,”
  10. (2002). Bierhoff et al., “c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant,”
  11. (2004). Biology of gastrointestinal stromal tumors,”
  12. (1999). C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of cajal),” Japanese J o u r n a lo fC a n c e rR e s e a r c h ,
  13. (2000). Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene,”
  14. (1998). CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than
  15. (1994). CD34 expression by gastrointestinal tract stromal tumors,”
  16. (2001). Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy,”
  17. (2008). Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases,”
  18. (1995). Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factordependent hematopoietic cell lines,”
  19. (2008). Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 studybycancerandleukemiagroupBandsouthwestoncology group,”
  20. (2008). D e M a t t e o ,J .S .G o l d ,L .S a r a ne ta l . ,“ T u m o rm i t o t i c rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor
  21. (2002). D e m e t r i ,M .v o nM e h r e n ,C .D .B l a n k ee ta l . ,“ E fficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” New England
  22. (2006). Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach,”
  23. (2003). Deletion of Trp557 and Lys-558 in the juxtamembrane domain of the ckit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors,”
  24. (2005). Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research
  25. (1998). DevelopmentaloriginandKit-dependentdevelopmentofthe interstitial cells of Cajal in the mammalian small intestine,”
  26. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach,”
  27. (2007). Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecularPathology Research International 7 genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors,”
  28. (2004). Differential expression of KIT/PDGFRA mutant isoforms in epithelioid andmixedvariantsofgastrointestinalstromaltumorsdepends predominantly on the tumor site,”
  29. (2006). dose selection for imatinib in patients with advanced gastrointestinalstromaltumours,”EuropeanJournalofCancer,
  30. (2004). Duensing et al., “KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications,”
  31. (1986). e s m e r ,J .E .M u r p h y ,P .C .G e o r g ee ta l . ,“ An e wa c u t e transformingfelineretrovirusandrelationshipofitsoncogene v-kit with the protein kinase gene family,”
  32. (2008). e,G.D .Demetri,M.vonM ehrenetal.,“Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing
  33. (1999). Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors,”
  34. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,”
  35. (2000). Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome,”
  36. (2005). Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred,”
  37. (2001). Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene,”
  38. (2002). Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation
  39. (1998). Familial gastrointestinal stromal tumours with germline mutation
  40. (2003). G.Sommer,V.Agosti,I.Ehlersetal.,“Gastrointestinalstromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase,”
  41. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors,”
  42. (2003). Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors,”
  43. (2005). Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up,”
  44. (2003). Gastrointestinal stromal tumors with internal tandem duplications in 3 end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course,”
  45. (1995). Gastrointestinal stromal tumors—value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas,”AmericanJournalofSurgicalPathology,vol.19,
  46. (2005). Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features,”
  47. (1999). Gastrointestinal stromal tumors: recent advances in understanding of their biology,”
  48. (1999). Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases,”
  49. (2004). Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity,”
  50. (1999). Generation of slow waves in membrane potential is an intrinsic property of interstitial cells of Cajal,”
  51. (2001). Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa,”
  52. (2000). Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors,”
  53. (2007). H.W¨ unsch,F.Hofstaedteretal.,“MinuteGastric Sclerosing Stromal Tumors (GIST Tumorlets) are common in adults and frequently show c-KIT mutations,”
  54. (1989). Human PDGFA receptor gene maps to the same region on
  55. (1999). Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxtamembrane region,”
  56. (1991). Interstitial cells of Cajal in human small intestine: ultrastructural identification and organization between the main smooth muscle layers,”
  57. Interstitial cells of Cajal: intestinal pacemaker cells?”
  58. (1989). Isolation of a novel receptor cDNA establishes the existence of two
  59. (1996). K.M.Sanders,“AcaseforinterstitialcellsofCajalaspacemakers and mediators of neurotransmission in the gastrointestinal tract,”
  60. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor,”
  61. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors,”
  62. (2000). KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors,”
  63. (2002). KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size,”
  64. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants,”
  65. (2004). Mechanisms ofoncogenicKITsignaltransductioninprimarygastrointestinal stromal tumors (GISTs),”
  66. (1998). MeisKindblom,“Gastrointestinalpacemakercelltumor(GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal,”
  67. (1999). Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms
  68. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors,”JournalofClinicalOncology,vol.24,no.29,pp.4764– 4774,
  69. (1999). Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia,”
  70. (1999). Mutations in exon 11 of c-kit occur preferentially in malignantversusbenigngastrointestinalstromaltumorsanddonot occur in leiomyomas or leiomyosarcomas,”
  71. (2000). Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of 200 cases,”
  72. (1999). Mutations of c-kit JM domain are found in a minoritry of human gastrointestinal stromal tumors,”
  73. (2003). mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors,”
  74. (2007). Mutationsingastrointestinalstromaltumors—apopulationbased study from northern Norway,”
  75. (2004). Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene,” Human Pathology,
  76. (2005). Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation,”
  77. (2005). Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis,”
  78. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors,”
  79. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor,”
  80. (2005). PDGFRA mutationsin gastrointestinalstromaltumors:frequency, spectrum and in vitro sensitivity to imatinib,”
  81. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033,”
  82. Regulation and targets of receptor tyrosine kinases,”EuropeanJournalofCancer,vol.38,pp.S3–S10,2002.
  83. (1992). Requirement of c-kit for development of intestinal pacemaker system,”
  84. (2006). Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer,”
  85. (2007). Second line therapies for the treatment of gastrointestinal stromal tumor,”
  86. Signal transduction via the stem cell factor receptor/c-Kit,”
  87. (1941). Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues,”
  88. (1985). Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years,”
  89. (1986). Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn’t know,”
  90. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase,”
  91. (2005). The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated,”
  92. (2004). Use of c-KIT/PDGFRA mutational analysis to predict the clinical responsetoimatinibinpatientswithadvancedgastrointestinal stromal tumours entered on phase I and II
  93. (1995). W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity,”
  94. (1991). Westermark Heldin, “Activation of the human ckit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis,”
  95. (1991). Yoshinaga et al., “In utero manipulation of coat color formation by a monoclonal antic-kit antibody: two distinct waves of c-kit-dependency during melanocyte development,”
  96. (2004). Zalcberg et al., “Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial,”